TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years,~* Fetal Infection with CMV authenticated by the positivity of the research of the viral genome by PCR in the amniotic liquid,~* Echographic Assessment revealing at least one cerebral extra anomaly being able to be in connection with the infection with CMV,~* Absence of request for termination of pregnancy from the start,~* Acceptance of a strict follow-up by a Multi-field Center of Prenatal diagnosis and of an optimal observance of the founded treatment,~* Collection of the written assent to take part in the test.~* Affiliation with a mode of social security or equivalent~Exclusion Criteria:~* No affiliation with a mode of social security (profit or having right)~* Patient of less than 18 years,~* Patient presenting another pathology obstetrical or medical (in particular hepatic or renal) preexistent to tracking or contra-indicating the use of valacyclovir,~* Patients whose fetus does not present any echographic sign being able to be in connection with the infection with CMV,~* Patients whose fetus presents at least one cerebral echographic anomaly:IntraparenchymalVentriculomegaly measured with the ventricular crossroads ≥ 12mm~  * Hyperechogenicity periventricular~ * Hydrocephaly~ * Intra-ventricular adherence~ * Microcephaly~ * Increase cuts large retro-cerebellar cistern~ * Hypoplasia vermis~ * Intraparenchymal calcifications~ * Porencephaly~ * Lissencephaly~ * Cysts periventricular~ * Hypoplasia of the callous body~ * Signs of LENTICULO-striated vasculopathy~* Patient under any other active antiviral treatment against CMV,~* Patient taking part in another therapeutic test,~* Patient refusing to sign the enlightened assent,~* Patient formulating a request for medical interruption of pregnancy before inclusion

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZELITREX (Type: EXPERIMENTAL): ZELITREX
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Simplified Severe Sepsis Protocol in Zambia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Suspected infection~* 2 or more of SIRS criteria:~  * Heart rate \>90/min~ * Respiratory rate \>20/min~ * Temperature \>= 38° C or \<= 36° C~ * White blood count \> 12,000 or \< 4,000/µL~* 1 or more of the following signs of end-organ dysfunction~  * Systolic blood pressure \< 90 mm Hg~ * Mean arterial blood pressure (MAP) \< 65 mm Hg~ * Confusion/altered mentation~ * Urine output \< 0.5 mL/kg/hr~ * Creatinine increase \> 0.5 mg/dL~ * Creatinine \> 0.5 mg/dL above upper limit of normal~ * Platelet \< 100x109/L~ * Respiratory rate \> 40/min~ * Jaundice~Exclusion Criteria:~* GI bleed~* Need for urgent surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simplified Severe Sepsis Protocol (Type: EXPERIMENTAL): This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
- Usual care (Type: ACTIVE_COMPARATOR): Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: 3T MR Angiography of the Hepatic Vasculature

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects that fulfill the criteria for living liver donation and are evaluated for the procedure with CT and MR.~Exclusion Criteria:~* Unable to give informed consent~* Unable to comply with breathing or other imaging related instructions resulting in inability to obtain diagnostic quality MRI studies~* Not suitable to undergo MRI with a gadolinium-based contrast agent because of:~  * Claustrophobia, unless patient agrees to sedation measures per institutional standard practice during MR imaging~ * Presence of metallic objects or implanted medical devices in body per institutional safety standards~ * Weight greater than that allowable by the MR table~ * Renal failure, as determined by estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 by the Modification of Diet in Renal Disease (MDRD) model based on a serum creatinine level obtained within 28 days prior to enrollment~ * Known allergy-like reaction to contrast media (gadolinium) or moderate or severe allergic reactions to one or more allergens as defined by the American College of Radiology (ACR), and unwillingness to undergo pre-treatment as defined by the institution's policy and/or ACR guidance~ * Pregnancy (if a female is of childbearing potential --defined as a premenopausal female capable of becoming pregnant --a pregnancy test should be done)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Subjects who fulfill the criteria for living liver donation (Type: OTHER): Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Permacol Use in Infected Fields

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have given written Informed Consent~* Be 18-85 years of age (inclusive)~* Have prosthetic mesh that is in proximity to an infected wound that has failed conservative management for at least 3 months, with mesh exposure and a draining wound, or that is in proximity to an abscess that requires operative intervention.~* Have a wound characterized by purulent discharge, positive gram stain or positive culture to document infection~* Be a candidate for surgical removal of infected mesh placed for repair of ventral/incisional hernias and concomitant abdominal wall reconstruction~* Have an ASA Score ≤3~* Have a body mass index (BMI) between 16.5 and 40 inclusive~* Be a candidate for anticipated primary approximation of skin/wound~* Have a life expectancy of at least 18 months~* Be willing to allow biopsy of implant if secondary wound opening is performed or spontaneous implant exposure occurs~Exclusion Criteria:~* Have loss of abdominal domain such that the operation would be impractical or would adversely effect respiratory or cardiovascular function to an unacceptable degree~* Have an enterocutaneous fistula in proximity to wound/mesh~* Be a candidate for emergency surgery that would make giving valid Informed Consent impractical~* Be currently taking part in another clinical study that conflicts with the current study~* Have known allergy to porcine collagen products~* Have active generalized peritonitis or intraperitoneal sepsis~* Have active necrotizing fasciitis~* Have active abdominal compartment syndrome~* Have active untreated metabolic or systemic illness~* Report unintentional weight loss \>10% of body weight in the previous 90 days~* Have known collagen metabolism disorder.(e.g., Ehlers-Danlos syndrome)~* Have known altered immune response (e.g., HIV or other immunodeficiency disorder))~* Have chronic renal failure~* Have known active malignancy present~* Have history of systemic chemotherapy within previous 1 year~* Have lifetime history of radiation to the abdomen, pelvis or thorax~* Have inguinal or groin hernia as primary diagnosis~* Be currently pregnant or planning to become pregnant during study period~* Be unable to give valid informed consent or comply with required follow- up schedule~* Suffer from mental capacity sufficiently severe to make informed consent unobtainable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Permacol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Levels in Smith Magenis Syndrome (SMS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Control participants:~  * 30 individuals: ages 55-85,~ * healthy without significant active medical problems.~* SMS patients:~  * 20 individuals: ages 3-50,~ * with a clinical diagnosis of Smith-Magenis Syndrome by a qualified Medical Geneticist, confirmed by cytogenetic analysis documenting deletion of chromosome band 17p11.2.~Exclusion Criteria:~* Control participants:~  * A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual, abnormal heart, liver or kidney function, diagnoses of neurodegenerative or cerebrovascular disease (Alzheimer's disease, Parkinson's disease, stroke, etc.),~ * cognitive impairment (Mini-Mental State Score \< 23) but without a formal diagnosis of dementia,~ * active symptoms of depression (Geriatric Depression Scale: 30 pt. version \> 10),~ * current diagnosis of cataracts,~ * macular degeneration or retinopathy based on eye exam by an optometrist or ophthalmologist within the past year.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
- 1 (Type: EXPERIMENTAL): Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be patients between the ages of 18 years and 65 years who have been diagnosed with Pompe Disease, confirmed by mutational analysis and/or GAA enzyme activity assay.~* Receiving rhGAA ERT~* Willing to travel to the study site for study assessments~* Willingness of local medical treatment provider to continue treating study participant with addition of Zavesca® to treatment plan.~* Willingness of study participant to modify dietary intake on day of infusion \*All Subjects will continue enzyme replacement therapy as standard of care, as prescribed by local medical treatment provider during the course of the Study.~Exclusion Criteria:~* Subject is unable to meet the study requirements~* Subject's medical condition contraindicates participation or Study Investigators feel that participation is otherwise not in the Subject's best interest~* Subject does not receive ERT treatment~* Participation in other interventional studies at the time of enrollment that may interfere with this study (at the investigator's discretion)~* Unable to travel to the University of Florida for study visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zavesca® 100 mg (Type: ACTIVE_COMPARATOR): 3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
- Zavesca® 300 mg (Type: ACTIVE_COMPARATOR): 3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Cardiac Resynchronization Therapy in Patients With RBBB

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: Included patients will have:~* sinus rhythm or isolated atrial pacing~* LV systolic dysfunction (EF \<35% at time of device implant)~* AV conduction \<250 ms, RBBB, and~* have an implanted CRT device based on the ACC/AHA/HRS guidelines (2, 18) or will have a CRT device implanted during the study enrollment per ACC/AHA/HRS guidelines (2).~Exclusion Criteria:~* atrial fibrillation~* atrial flutter~* atrial tachycardia~* AV delay \> 250 ms~* sinus tachycardia with resting heart rate at time of the study 100 bpm~* frequent APCs (\> 25% of the total beats/min) or PVCs (\>20% of the total beats/min), or~* patients with EF \> 40% at time of enrollment (if LV systolic function was found to be improved from time of implant).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- CRT Optimization (Type: OTHER): Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be over 18~* carry a tight and symptomatic aortic stenosis~* have an indication for a ballon aortic valvuloplasty~* Subject have signed his written informed consent~Exclusion Criteria:~* Have an absence of femoral surgical approach~* have a criticial hemodynamic state, considered as outdrove for the treatment~* have a severe aortic failure~* allergia to heparin~* contraindication to heparin or/and local anaesthetic~* be treted by low molecular weight heparin in less than 12 hoursbefore the intervention or by standard heparin in less than 4 hours before the valvulopasty~* have a tight but not symptomatic aortic stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heparin (Type: EXPERIMENTAL): injection of unfractionated heparin (50 IU / kg)
- NaCl (Type: PLACEBO_COMPARATOR): without heparin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Infection caused by Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, or Enterococcus faecium that requires inpatient hospitalization and treatment with injectable antibiotics\*\*~* Site of infection: complicated skin and skin structure infection; urinary tract infection; intra-abdominal infection; infective endocarditis; or bloodstream infection (including catheter-related).~* Pathogen resistant to, or patient intolerant of: beta-lactams, vancomycin, quinupristin/dalfopristin, or linezolid.~* Unable to receive any other standard commercially available antibacterial therapy for the infection.~Main Exclusion Criteria:~* Creatinine clearance less than 40 mL/min\*\*~* Hemodialysis or peritoneal dialysis~* Admitted to the hospital for drug overdose or other conditions associated with rhabdomyolysis, or is expected to require repeated intramuscular injections~* Creatine phosphokinase (CPK) level greater than 2.5 times above the upper limit of normal (ULN) at screening; if the elevation in CPK can be attributed to an obvious cause (eg, surgery)\*\*~* Central nervous system infection~* Pulmonary infection.~(\*\*) An exemption may be granted for patients not satisfying these criteria following a conversation with the Medical Monitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. An existing diagnosis of diabetes mellitus, either T1DM or T2DM~2. Absence of cognitive impairment, as demonstrated by a Montreal Cognitive Assessment (MOCA) score greater than 26; those individuals with questionable cognitive ability will be screened with this instrument.~3. Ability to provide informed consent for participation.~Exclusion Criteria:~1. Individuals without diabetes~2. Those who have a MOCA score of 26 or less~3. Those who cannot speak or read English. The investigators are limiting participation to those who read and speak English, as this is a pilot study of a small number of participants, that will very unlikely offer the prospect of direct benefit from participating.~4. Individuals who have a cardiac, respiratory, or other condition that would preclude safely exercising at a moderate pace. Along with a medical history and physical examination by the PI, prospective participants will complete the Physical Activity Readiness Questionnaire (PAR-Q) to help determine those who may safely exercise for this study. One or more yes responses does not necessarily exclude an individual from participating.~5. Individuals who have frequent hypoglycemia, hypoglycemia unawareness, or who are at high risk for hypoglycemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Wearing glucose sensor (Type: EXPERIMENTAL): The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy